Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3135017 | 0.97 | NR1H4 (0.38) | NR1H4MAPK14CXCR3RXRARXRB | |
| SCHEMBL3136182 | 0.89 | MCL1 (0.33) | NR1H4MAPK14MCL1KEAP1NFE2L2 | |
| SCHEMBL212551 | 0.88 | RXRB (0.43) | NR1H4RXRARXRBRXRGMCL1 | |
| Potassium SCHEMBL214696 | 0.88 | RXRB (0.42) | NR1H4RXRARXRBRXRGMCL1 | |
| SCHEMBL215438 | 0.88 | RXRB (0.42) | NR1H4RXRARXRBRXRGMCL1 | |
| SCHEMBL215440 | 0.88 | RXRB (0.42) | NR1H4RXRARXRBRXRGMCL1 | |
| SCHEMBL214694 | 0.88 | RXRB (0.42) | NR1H4RXRARXRBRXRGMCL1 | |
| SCHEMBL214741 | 0.86 | NR1H4 (0.43) | NR1H4RXRARXRBRXRGMCL1 | |
| SCHEMBL216100 | 0.84 | NR1H4 (0.45) | NR1H4RXRARXRBRXRGMCL1 | |
| SCHEMBL3144471 | 0.84 | NR1H4 (0.40) | NR1H4CXCR3RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181187-B2 | Therapeutic agent for urinary excretion disorder | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| EP-2123273-B1 | THERAPEUTIC AGENT FOR URINARY EXCRETION DISORDER | ONO PHARMACEUTICAL CO (JP) | 2013-10-23 | — | — | EP | disclosed |
| US-20100076038-A1 | THERAPEUTIC AGENT FOR URINARY EXCRETION DISORDER | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-03-25 | — | — | US | disclosed |
| EP-2123273-A1 | THERAPEUTIC AGENT FOR URINARY EXCRETION DISORDER | ONO Pharmaceutical Co., Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076038-A1 | THERAPEUTIC AGENT FOR URINARY EXCRETION DISORDER | PTGER1, TMPRSS15, EPDR1 | NR1H4 1549/4885MAPK14 1924/4885CXCR3 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.